• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

迄今为止报道的最良性纤维发育不良性骨化进展变异病例中,在甘氨酸/丝氨酸丰富区发现了一种新型的 ACVR1 突变。

A novel ACVR1 mutation in the glycine/serine-rich domain found in the most benign case of a fibrodysplasia ossificans progressiva variant reported to date.

机构信息

Musculoskeletal Research Unit, School of Clinical Sciences, University of Bristol, Bristol, UK.

出版信息

Bone. 2011 Mar 1;48(3):654-8. doi: 10.1016/j.bone.2010.10.164. Epub 2010 Oct 29.

DOI:10.1016/j.bone.2010.10.164
PMID:21044902
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3160462/
Abstract

Fibrodysplasia Ossificans Progressiva (FOP) is a rare, autosomal dominant condition, classically characterised by heterotopic ossification beginning in childhood and congenital great toe malformations; occurring in response to a c.617 G > A ACVR1 mutation in the functionally important glycine/serine-rich domain of exon 6. Here we describe a novel c.587 T > C mutation in the glycine/serine-rich domain of ACVR1, associated with delayed onset of heterotopic ossification and an exceptionally mild clinical course. Absence of great toe malformations, the presence of early ossification of the cervical spine facets joints, plus mild bilateral camptodactyly of the 5th fingers, together with a novel ACVR1 mutation, are consistent with the 'FOP-variant' syndrome. The c.587 T > C mutation replaces a conserved leucine with proline at residue 196. Modelling of the mutant protein reveals a steric clash with the kinase domain that will weaken interactions with FKBP12 and induce exposure of the glycine/serine-rich repeat. The mutant receptor is predicted to be hypersensitive to ligand stimulation rather than being constitutively active, consistent with the mild clinical phenotype. This case extends our understanding of the 'FOP-variant' syndrome.

摘要

进行性骨化性纤维发育不良(FOP)是一种罕见的常染色体显性疾病,其特征通常为儿童期开始的异位骨化和先天性大脚趾畸形;这是由于 ACVR1 基因 6 号外显子功能重要的甘氨酸/丝氨酸丰富区发生 c.617G > A ACVR1 突变所致。在此,我们描述了一种新型的 ACVR1 甘氨酸/丝氨酸丰富区 c.587T > C 突变,其与异位骨化的迟发发作和异常轻微的临床病程有关。没有大脚趾畸形,颈椎小关节的早期骨化,以及双侧第 5 指轻度的屈指畸形,加上新型的 ACVR1 突变,与“FOP 变异型”综合征一致。c.587T > C 突变将残基 196 处的保守亮氨酸突变为脯氨酸。突变蛋白的建模显示与激酶结构域存在空间冲突,这将削弱与 FKBP12 的相互作用,并诱导甘氨酸/丝氨酸丰富重复序列的暴露。该突变受体被预测对配体刺激更为敏感,而不是持续激活,这与轻微的临床表型一致。该病例扩展了我们对“FOP 变异型”综合征的认识。

相似文献

1
A novel ACVR1 mutation in the glycine/serine-rich domain found in the most benign case of a fibrodysplasia ossificans progressiva variant reported to date.迄今为止报道的最良性纤维发育不良性骨化进展变异病例中,在甘氨酸/丝氨酸丰富区发现了一种新型的 ACVR1 突变。
Bone. 2011 Mar 1;48(3):654-8. doi: 10.1016/j.bone.2010.10.164. Epub 2010 Oct 29.
2
Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1.典型和非典型进行性骨化性纤维发育不良(FOP)表型是由骨形态发生蛋白(BMP)I型受体ACVR1中的突变引起的。
Hum Mutat. 2009 Mar;30(3):379-90. doi: 10.1002/humu.20868.
3
ACVR1 (587T>C) mutation in a variant form of fibrodysplasia ossificans progressiva: second report.进行性骨化性纤维发育不良变异型中的ACVR1(587T>C)突变:第二篇报告。
Am J Med Genet A. 2014 Jan;164A(1):220-4. doi: 10.1002/ajmg.a.36219. Epub 2013 Nov 20.
4
Mutational analysis of the ACVR1 gene in Italian patients affected with fibrodysplasia ossificans progressiva: confirmations and advancements.意大利进行性骨化性纤维发育不良患者ACVR1基因的突变分析:验证与进展
Eur J Hum Genet. 2009 Mar;17(3):311-8. doi: 10.1038/ejhg.2008.178. Epub 2008 Oct 1.
5
Rarely occurring mutation of ACVR1 gene in Moroccan patient with fibrodysplasia ossificans progressiva.摩洛哥进行性骨化性纤维发育不良患者中 ACVR1 基因罕见突变。
Clin Rheumatol. 2010 Jan;29(1):119-21. doi: 10.1007/s10067-009-1283-z. Epub 2009 Oct 1.
6
A case of Fibrodysplasia Ossificans Progressiva associated with a novel variant of the ACVR1 gene.一例与 ACVR1 基因新型变异相关的进行性骨化性纤维发育不良。
Mol Genet Genomic Med. 2021 Oct;9(10):e1774. doi: 10.1002/mgg3.1774. Epub 2021 Aug 4.
7
ACVR1 p.Q207E causes classic fibrodysplasia ossificans progressiva and is functionally distinct from the engineered constitutively active ACVR1 p.Q207D variant.激活素受体1基因(ACVR1)的第207位密码子由脯氨酸突变为谷氨酸(p.Q207E)会导致典型的进行性骨化性纤维发育不良,且在功能上与人工构建的组成型激活的激活素受体1基因第207位密码子由脯氨酸突变为天冬氨酸(p.Q207D)变体不同。
Hum Mol Genet. 2014 Oct 15;23(20):5364-77. doi: 10.1093/hmg/ddu255. Epub 2014 May 22.
8
The ACVR1 R206H mutation found in fibrodysplasia ossificans progressiva increases human induced pluripotent stem cell-derived endothelial cell formation and collagen production through BMP-mediated SMAD1/5/8 signaling.在进行性骨化性纤维发育不良中发现的ACVR1 R206H突变通过BMP介导的SMAD1/5/8信号通路增加人诱导多能干细胞衍生的内皮细胞形成和胶原蛋白生成。
Stem Cell Res Ther. 2016 Aug 17;7(1):115. doi: 10.1186/s13287-016-0372-6.
9
[A Chinese girl with fibrodysplasia ossificans progressiva caused by a de novo mutation R206H in ACVR1 gene].一名因ACVR1基因新发R206H突变导致进行性骨化性纤维发育不良的中国女孩
Zhonghua Er Ke Za Zhi. 2008 Mar;46(3):215-9.
10
Fibrodysplasia ossificans progressiva: middle-age onset of heterotopic ossification from a unique missense mutation (c.974G>C, p.G325A) in ACVR1.进行性骨化性纤维发育不良:ACVR1 中独特的错义突变(c.974G>C,p.G325A)导致中年发病的异位骨化。
J Bone Miner Res. 2012 Mar;27(3):729-37. doi: 10.1002/jbmr.1473.

引用本文的文献

1
Fibrodysplasia ossificans progressiva: genetic and clinical characterization in a cohort of Polish patients and review of potential therapies.进行性骨化性纤维发育不良:一组波兰患者的遗传学和临床特征及潜在治疗方法综述
J Appl Genet. 2025 Apr 12. doi: 10.1007/s13353-025-00966-4.
2
A blocking monoclonal antibody reveals dimerization of intracellular domains of ALK2 associated with genetic disorders.一种阻断性单克隆抗体揭示了与遗传疾病相关的 ALK2 细胞内结构域的二聚化。
Nat Commun. 2023 May 25;14(1):2960. doi: 10.1038/s41467-023-38746-5.
3
Protocol paper: a multi-center, double-blinded, randomized, 6-month, placebo-controlled study followed by 12-month open label extension to evaluate the safety and efficacy of Saracatinib in Fibrodysplasia Ossificans Progressiva (STOPFOP).方案论文:一项多中心、双盲、随机、6 个月、安慰剂对照研究,随后进行 12 个月的开放标签扩展,以评估 Saracatinib 在纤维发育不良性骨化进展症(STOPFOP)中的安全性和疗效。
BMC Musculoskelet Disord. 2022 Jun 1;23(1):519. doi: 10.1186/s12891-022-05471-x.
4
Retinoid Agonists in the Targeting of Heterotopic Ossification.视黄酸激动剂在异位骨化靶向治疗中的应用。
Cells. 2021 Nov 19;10(11):3245. doi: 10.3390/cells10113245.
5
Accumulated Knowledge of Activin Receptor-Like Kinase 2 (ALK2)/Activin A Receptor, Type 1 (ACVR1) as a Target for Human Disorders.作为人类疾病靶点的激活素受体样激酶2(ALK2)/激活素A受体1型(ACVR1)的累积知识。
Biomedicines. 2021 Jun 26;9(7):736. doi: 10.3390/biomedicines9070736.
6
Insight into Molecular Mechanism for Activin A-Induced Bone Morphogenetic Protein Signaling.深入了解激活素 A 诱导骨形态发生蛋白信号转导的分子机制。
Int J Mol Sci. 2020 Sep 5;21(18):6498. doi: 10.3390/ijms21186498.
7
ACVR1 Function in Health and Disease.ACVR1 在健康和疾病中的作用。
Cells. 2019 Oct 31;8(11):1366. doi: 10.3390/cells8111366.
8
Analysis of clinical manifestations and treatment in 26 children with fibrodysplasia ossificans progressiva in China.中国 26 例进行性骨化性纤维发育不良患儿的临床表现与治疗分析。
World J Pediatr. 2020 Feb;16(1):82-88. doi: 10.1007/s12519-019-00302-x. Epub 2019 Sep 16.
9
The role of Activin A in fibrodysplasia ossificans progressiva: a prominent mediator.激活素A在进行性骨化性纤维发育不良中的作用:一种重要的介质。
Biosci Rep. 2019 Aug 2;39(8). doi: 10.1042/BSR20190377. Print 2019 Aug 30.
10
Recent Topics in Fibrodysplasia Ossificans Progressiva.进行性骨化性纤维发育不良的近期研究热点
Endocrinol Metab (Seoul). 2018 Sep;33(3):331-338. doi: 10.3803/EnM.2018.33.3.331.

本文引用的文献

1
ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation.ALK2 R206H 突变与进行性骨化性纤维发育不良相关,赋予 BMP Ⅰ型受体组成型活性,并使间充质细胞对 BMP 诱导的成骨细胞分化和骨形成敏感。
J Bone Miner Res. 2010 Jun;25(6):1208-15. doi: 10.1359/jbmr.091110.
2
The fibrodysplasia ossificans progressiva R206H ACVR1 mutation activates BMP-independent chondrogenesis and zebrafish embryo ventralization.进行性骨化性纤维发育不良的R206H ACVR1突变激活不依赖骨形态发生蛋白的软骨生成并导致斑马鱼胚胎腹化。
J Clin Invest. 2009 Nov;119(11):3462-72. doi: 10.1172/JCI37412. Epub 2009 Oct 12.
3
Mutational screening of ACVR1 gene in Brazilian fibrodysplasia ossificans progressiva patients.巴西骨化性纤维发育不良进展期患者 ACVR1 基因的突变筛查。
Clin Genet. 2010 Feb;77(2):171-6. doi: 10.1111/j.1399-0004.2009.01256.x. Epub 2009 Oct 1.
4
Rarely occurring mutation of ACVR1 gene in Moroccan patient with fibrodysplasia ossificans progressiva.摩洛哥进行性骨化性纤维发育不良患者中 ACVR1 基因罕见突变。
Clin Rheumatol. 2010 Jan;29(1):119-21. doi: 10.1007/s10067-009-1283-z. Epub 2009 Oct 1.
5
ACVR1 gene mutation in sporadic Korean patients with fibrodysplasia ossificans progressiva.散发性韩国进行性骨化性纤维发育不良患者的ACVR1基因突变
J Korean Med Sci. 2009 Jun;24(3):433-7. doi: 10.3346/jkms.2009.24.3.433. Epub 2009 Jun 12.
6
Novel mutations in ACVR1 result in atypical features in two fibrodysplasia ossificans progressiva patients.ACVR1基因的新突变导致两名进行性骨化性纤维发育不良患者出现非典型特征。
PLoS One. 2009;4(3):e5005. doi: 10.1371/journal.pone.0005005. Epub 2009 Mar 30.
7
Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1.典型和非典型进行性骨化性纤维发育不良(FOP)表型是由骨形态发生蛋白(BMP)I型受体ACVR1中的突变引起的。
Hum Mutat. 2009 Mar;30(3):379-90. doi: 10.1002/humu.20868.
8
Mutational analysis of the ACVR1 gene in Italian patients affected with fibrodysplasia ossificans progressiva: confirmations and advancements.意大利进行性骨化性纤维发育不良患者ACVR1基因的突变分析:验证与进展
Eur J Hum Genet. 2009 Mar;17(3):311-8. doi: 10.1038/ejhg.2008.178. Epub 2008 Oct 1.
9
Constitutively activated ALK2 and increased SMAD1/5 cooperatively induce bone morphogenetic protein signaling in fibrodysplasia ossificans progressiva.组成性激活的ALK2和增加的SMAD1/5协同诱导进行性骨化性纤维发育不良中的骨形态发生蛋白信号传导。
J Biol Chem. 2009 Mar 13;284(11):7149-56. doi: 10.1074/jbc.M801681200. Epub 2008 Aug 6.
10
Insights from a rare genetic disorder of extra-skeletal bone formation, fibrodysplasia ossificans progressiva (FOP).来自一种罕见的骨骼外骨形成遗传性疾病——进行性骨化性纤维发育不良(FOP)的见解。
Bone. 2008 Sep;43(3):427-33. doi: 10.1016/j.bone.2008.05.013. Epub 2008 May 28.